NCT06819826View on ClinicalTrials.gov

A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria

PHASE3RecruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

February 14, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
IgA Nephropathy (IgAN)
Interventions
DRUG

SC0062 strength 10mg

Subjects will take 20 mg once daily for 108 weeks during the treatment period.

DRUG

Placebo matched to SC0062

Subjects will take 20 mg once daily for 108 weeks during the treatment period.

Trial Locations (1)

510800

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

Sponsors
All Listed Sponsors
lead

Biocity Biopharmaceutics Co., Ltd.

INDUSTRY

NCT06819826 - A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria | Biotech Hunter | Biotech Hunter